JAMA Neurology published a phase III study showing Sanbexin® sublingual tablets significantly improved neurological functions and daily living activities in acute ischemic stroke patients.
JAMA Neurology published the key findings of a phase III clinical study investigating Sanbexin® sublingual tablets (a combination of edaravone and dexborneol) for the treatment of acute ischemic stroke (AIS). The findings indicate that Sanbexin® sublingual tablets significantly improved neurological functions and daily living activities among AIS patients. Developed by Simcere Pharmaceutical Group Ltd. and Neurodawn Pharmaceutical Co., Ltd., the innovative drug is expected to become a sequential therapy with Simcere's marketed Sanbexin® (Edaravone and Dexborneol Concentrated Solution).
February 20, 2024
7 Articles